Original ResearchNivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Under a Creative Commons license
open access
Keywords
Antineoplastic agents
Carcinoma
Ipilimumab
Lung neoplasms
Nivolumab
Non–small-cell lung cancer
Platinum-doublet chemotherapy
Quality of life
Surveys and questionnaires
Cited by (0)
© 2019 The Authors. Published by Elsevier Ltd.